Enbrel

Wyeth presented at a conference yesterday and spoke about all of their recent drugs and drugs in their pipeline. Here is a highlight about Enbrel.

ENBREL(R) (etanercept) for Psoriasis
The presentation also covered an important new regulatory filing pending
outside the U.S. for ENBREL for the treatment of psoriasis, an indication
recently approved by the U.S. FDA. More than 75 percent of psoriasis patients
are dissatisfied with their current therapy. In clinical trials, psoriasis
sufferers who used ENBREL showed rapid and sustained effects in the treatment
of chronic moderate to severe psoriatic plaques, with an absence of disease
flare when treatment was withdrawn and a drug safety profile similar to other
approved patient populations. Retreatment results were also similar to
initial results. Beyond psoriasis, ENBREL is also being investigated for
other TNF-mediated diseases such as idiopathic pulmonary fibrosis and asthma,
with proof-of-concept studies ongoing.

Did you get that? 75% of all Psoriasis patients are unhappy with their treatment!